However, in line with our results, other drug utilization studies have reported that fewer than 1% of patients with ASCVD and/or heterozygous familial hypercholesterolemia added ezetimibe to statin therapy, and fewer than 1% of patients were prescribed PCSK9 inhibitors [24]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.